Zacks Research Forecasts Stryker’s Q2 Earnings (NYSE:SYK)

Stryker Corporation (NYSE:SYK) – Analysts at Zacks Research reduced their Q2 2027 EPS estimates for shares of Stryker in a research note issued to investors on Wednesday, November 19th. Zacks Research analyst Team now expects that the medical technology company will earn $3.72 per share for the quarter, down from their previous forecast of $3.85. The consensus estimate for Stryker’s current full-year earnings is $13.47 per share. Zacks Research also issued estimates for Stryker’s Q3 2027 earnings at $3.81 EPS.

Several other equities analysts also recently commented on the company. Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Truist Financial upped their price objective on Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a research note on Friday, November 14th. Evercore ISI cut their target price on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. Rothschild & Co Redburn assumed coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price on the stock. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Stryker in a research note on Monday, November 3rd. Thirteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $434.37.

Stryker Trading Up 2.2%

NYSE SYK opened at $368.35 on Friday. The company has a market cap of $140.87 billion, a price-to-earnings ratio of 48.79, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The business’s fifty day moving average is $369.38 and its 200 day moving average is $380.68.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS.

Insiders Place Their Bets

In other Stryker news, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 522,618 shares of company stock valued at $185,577,237 over the last 90 days. 5.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of SYK. Norges Bank bought a new stake in Stryker in the second quarter valued at $1,882,173,000. Alliancebernstein L.P. grew its stake in shares of Stryker by 307.6% in the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock valued at $2,214,146,000 after buying an additional 4,223,366 shares during the period. Nuveen LLC bought a new stake in Stryker in the 1st quarter valued at about $558,075,000. Corient Private Wealth LLC raised its stake in Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after buying an additional 1,146,998 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after acquiring an additional 1,021,496 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.